.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04B_DrugsForTreatmentOfLepra.J04BA51_DapsoneRifampicinAndClof.DapsoneRifampicinAndClof .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04B_DrugsForTreatmentOfLepra.J04BA51_DapsoneRifampicinAndClof.DapsoneRifampicinAndClof| name: | DapsoneRifampicinAndClofazimine | |
| ATC code: | J04BA51 | route: | oral |
| compartments: | 2 | |
| dosage: | 600 | mg |
| volume of distribution: | 20 | L |
| clearance: | 0.25 | L/h/kg |
| other parameters in model implementation | ||
This is a fixed-dose combination therapy containing dapsone, rifampicin, and clofazimine, primarily used for the treatment of leprosy (Hansen's disease). This combination is used as multi-drug therapy (MDT) to prevent resistance and is approved and recommended by the WHO. It is still the standard regimen for leprosy worldwide.
Pharmacokinetic estimates for the fixed-dose combination in healthy adults, with assumed average PK parameters based on published mono- and dual-therapy data. No studies directly reporting the full combined PK model for this combination found.